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22 Abstract 
23 Somato-dendritic secretion was first demonstrated over 30 years ago. However, while its existence 
24 has become widely accepted, the function of somato-dendritic secretion is still not completely 
25 understood. Hypothalamic magnocellular neurosecretory cells (MNCs) were among the first neuronal 
26 phenotypes in which somato-dendritic secretion was demonstrated and are among the neurones for 
27 which the functions of somato-dendritic secretion are best characterised. These neurones secrete the 
28 neuropeptides, vasopressin and oxytocin, in an orthograde manner from their axons in the posterior 
29 pituitary gland into the blood circulation to regulate body fluid balance and reproductive physiology. 
30 Retrograde somato-dendritic secretion of vasopressin and oxytocin modulate the activity of the 
31 neurones from which they are secreted, as well as the activity of neighbouring populations of 
32 neurones, to provide intra- and inter-population signals that coordinate the endocrine and autonomic 
33 responses for control of peripheral physiology. Somato-dendritic vasopressin and oxytocin have also 
34 been proposed to act as hormone-like signals in the brain. There is some evidence that somato-
35 dendritic secretion from MNCs modulates the activity of neurones beyond their local environment 
36 where there are no vasopressin- or oxytocin-containing axons but, to date, there is no conclusive 
37 evidence for, or against, hormone-like signalling throughout the brain, although it is difficult to 
38 imagine that the levels of vasopressin found throughout the brain could be underpinned by release 
39 from relatively sparse axon terminal fields; the generation of data to resolve this issue remains a 
40 priority for the field.
41 Information transfer in the central nervous system
42 The classical understanding of communication in the nervous system is of synaptic transmission in a 
43 unidirectional manner within networks from presynaptic neurones to postsynaptic neurones. However, 
44 it has become clear that information transfer in the central nervous system is more complex than 
45 simple point-to-point, unidirectional transmission between neurones at synapses. Among the 
46 additional mechanisms that contribute to information transfer in the nervous system is somato-
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47 dendritic secretion. Unlike classical synaptic transmission by neurotransmitters such as glutamate and 
48 GABA, which signals between pre- and postsynaptic neurones with spatial precision and high 
49 temporal resolution, somato-dendritic secretion causes longer-term changes than synaptic 
50 transmission that alters the overall excitability of neurones by modulating the strength of synaptic 
51 inputs and/or by modulating the baseline membrane potential. These effects can be autocrine or 
52 paracrine, on the neurone from which somato-dendritic secretion occurs or on nearby neurones, and 
53 might spread over relatively long distances to modulate the activity of neurones in brain areas distant 
54 from the site of secretion.
55 Somato-dendritic secretion occurs in many types of neurone and can involve many types of 
56 transmitter molecule (1). Magnocellular neurosecretory cells (MNCs) of the hypothalamic supraoptic 
57 nucleus (SON) and paraventricular nucleus (PVN) are among those for which the mechanisms and 
58 consequences of somato-dendritic secretion are best characterised. This review focusses on studies 
59 from the authors’ laboratories, some of which were presented at the 22nd International Symposium on 
60 Regulatory Peptides, which have contributed to our understanding of how somato-dendritic secretion 
61 from MNCs contributes to endocrine and autonomic regulation of peripheral physiology in health and 
62 disease.
63 The magnocellular neurosecretory system
64 The magnocellular neurosecretory system comprises MNCs that predominantly secrete either 
65 vasopressin (the antidiuretic hormone) or oxytocin into the general circulation from the posterior 
66 pituitary gland (neurohypophysis). The principal function of vasopressin is to maintain body fluid 
67 balance and blood pressure by activation of renal V2-receptors to increase water reabsorption from the 
68 urine and, when blood pressure/volume is decreased, by activation of vascular V1a-receptors (V1aRs) 
69 to cause vasoconstriction (2). The best-characterised physiological functions of oxytocin are to trigger 
70 uterine contractions during birth and milk ejection during lactation (2). However, oxytocin also 
71 contributes to body fluid balance by promoting natriuresis in the kidney (3) and by stimulating atrial 
72 natriuretic peptide secretion (4).
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73 The human hypothalamus contains over 100,000 MNCs (5), with ∼10,000 in the rat, that are 
74 principally located in the SON and PVN as well as in several accessory nuclei (6). MNCs each project 
75 a single axon to the posterior pituitary gland (Figure 1) and each axon branches extensively to form 
76 several thousand neurosecretory axon swellings and terminals (7) that are each tightly packed with 
77 dense core vesicles containing ~85,000 molecules of vasopressin or oxytocin in rats (8). Hormone 
78 secretion is triggered by action potential invasion of the neurosecretory swellings and terminals. It has 
79 been estimated that each MNC contains about 10 million dense core vesicles and secretes between 
80 100 and 10,000 dense core vesicles from the posterior pituitary gland every minute to maintain basal 
81 hormone concentrations in the circulation (9). Hence, the sustained output of the hormones, and the 
82 consequent regulation of peripheral physiology, depends on the average action potential discharge 
83 from the population (2, 10). 
84 MNCs also synthesise lesser amounts of other neurotransmitters and neuromodulators that can be 
85 contained in the same dense core vesicles as vasopressin or oxytocin (11), as well as glutamate-
86 containing microvesicles (12). To date, the only evidence of effects of these other neurotransmitters 
87 and neuromodulators on peripheral physiology is for secretin, which increases renal antidiuresis (13). 
88 Rather, their principal function appears to be modulation of hormone secretion at the level of the 
89 posterior pituitary gland, which is comprehensively reviewed elsewhere (14), and at the level of the 
90 somata and dendrites, as we describe here. 
91 Some MNCs project axon collaterals to other brain areas. Originally, these were thought to remain 
92 proximal to the SON (15) and PVN (16), projecting to local interneurones as part of a proposed local 
93 feedback loop. More recently, it was shown that some MNC axon collaterals project more broadly 
94 throughout the brain, with oxytocin MNCs projecting to the medial amygdala (MeA), central 
95 amygdala (CeA), nucleus accumbens (17) and the lateral septum (18), and vasopressin MNCs to the 
96 medial and lateral preoptic area, suprachiasmatic nucleus, lateral habenula, CeA, MeA (19, 20), locus 
97 coeruleus (21) and arcuate nucleus (ARC) (22). These axon collaterals have been implicated in the 
98 modulation of different behaviours, but it remains to be established how secretion from axon 
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99 collaterals to modulate behaviour relates to secretion from the posterior pituitary gland to modulate 
100 peripheral physiology.
101 MNCs possess 1 – 3 thick, varicose, aspiny dendrites of a few hundred micrometres in length. MNCs 
102 of the SON extend their dendrites to the ventral surface of the nucleus, where the dendrites bundle 
103 together within the ventral glial lamina (a layer of astrocytes on the ventral surface of the brain within 
104 the SON) (23) and MNCs of the PVN extend their dendrites towards the subependymal region of the 
105 third ventricle (24). In addition to being the site of afferent synaptic input, MNC dendrites are active 
106 players in shaping MNC activity through exocytosis of vasopressin and oxytocin (as well as other 
107 neurotransmitters/neuromodulators) into the extracellular space of the SON and PVN.
108 Somato-dendritic secretion from magnocellular neurosecretory cells
109 The somata and dendrites of MNCs are tightly packed with dense core vesicles containing either 
110 vasopressin or oxytocin (Figure 2), which undergo exocytosis to secrete their major neuropeptides 
111 (25, 26) along with lesser amounts of other co-packaged neurotransmitters and neuromodulators (11). 
112 Tannic acid capture of somato-dendritic secretion reveals that the entire vesicle content is released 
113 from MNCs (25).  
114 Unlike synaptic transmission by classical neurotransmitters, dense core vesicle exocytosis from the 
115 somata and dendrites of MNCs requires a sustained increase in intracellular calcium (27, 28,) and 
116 calcium buffering limits increases in cytoplasmic calcium to restrain the activation of somato-
117 dendritic secretion from MNCs (29). MNCs express different arrays of voltage-gated calcium 
118 channels in their somata and axon terminals (30). Relative to other voltage-gated calcium channels, 
119 N-type calcium channels (Cav2.2) carry a comparatively small current in MNC somata, but 
120 nevertheless contribute most significantly to somato-dendritic oxytocin secretion (31). While the 
121 primary trigger for somato-dendritic secretion is the influx of extracellular calcium, intracellular 
122 calcium release also contributes to somato-dendritic secretion from MNCs (27, 28). 
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123 Action potential invasion triggers exocytosis from axon terminals and MNC dendrites and appears to 
124 support depolarisation-induced calcium spikes (32). Capacitance measurements from isolated MNCs 
125 suggest that single action potentials trigger somato-dendritic secretion (33). However, functional 
126 studies suggest that sustained intracellular calcium release is required to trigger somato-dendritic 
127 secretion (27, 28). Furthermore, if every action potential fired by each MNC triggered somato-
128 dendritic secretion of a single dense core vesicle, the brain would be awash with vasopressin and 
129 oxytocin (34). Exocytosis of ~6,000 dense core vesicles per second has been calculated to be 
130 sufficient to maintain the concentrations of vasopressin and oxytocin measured in the rat 
131 hypothalamus (34). There are ~10,000 MNCs in the rat hypothalamus (6). While ~25% of MNCs are 
132 silent under basal conditions, active MNCs display a mean firing rate of ~5 Hz under basal conditions 
133 (35). Hence, up to 37,500 action potentials are fired by MNCs every second, which is almost 10-fold 
134 more than the number of dense core vesicles secreted. Hence, it is likely that trains of action potentials 
135 that cause a more sustained depolarisation and calcium influx are required to trigger somato-dendritic 
136 secretion from MNCs. Indeed, under basal conditions, some stimuli reduce the oxytocin MNC action 
137 potential firing rate but increase somato-dendritic oxytocin secretion (36, 37), and it was shown 
138 recently that action potential firing alone at physiological firing rates is insufficient to trigger 
139 measurable somato-dendritic secretion from indiviual vasopresin MNCs (38).
140 In addition to permeation through voltage-gated calcium channels, calcium influx also occurs through 
141 N-methyl-D-aspartate (NMDA) receptors (NMDARs), and synaptic NMDA receptors would be 
142 expected to further increase cytoplasmic calcium concentrations during action potential firing. 
143 Furthermore, MNCs express extrasynaptic NMDARs (39-41). While these extrasynaptic NMDARs 
144 are activated by basal glutamate levels in vitro (39), they are not activated under basal conditions in 
145 vivo, but are activated under stimulated conditions (35) and trigger somato-dendritic peptide secretion 
146 (38).
147 In addition to triggering somato-dendritic secretion, increased cytoplasmic calcium also promotes 
148 movement of dense core vesicles from the reserve pool toward the cell surface (42), where they are 
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149 ready for secretion in response to subsequent stimuli that raise cytoplasmic calcium. In parallel, 
150 increased intracellular calcium also promotes recruitment of N-type calcium channels (31) to make 
151 the system more sensitive to subsequent cytoplasmic calcium increases. Hence, this ‘priming’ 
152 increases somato-dendritic secretion triggered by subsequent signals that increase cytoplasmic 
153 calcium. 
154 Action potential-mediated depolarisation is not the only trigger for somato-dendritic secretion from 
155 MNCs. Vasopressin and oxytocin MNCs express their respective receptors (43, 44) and activation of 
156 these receptors increases cytoplasmic calcium concentrations (45) to trigger somato-dendritic 
157 secretion (27, 28). While vasopressin and oxytocin trigger somato-dendritic secretion from 
158 vasopressin and oxytocin MNCs without a prior stimulus to prime the system, once the MNCs are 
159 primed, the peptides can trigger a much greater somato-dendritic secretion (27, 28).
160 There is an elaborate network of actin and microtubules in MNC somata and dendrites (46, 47). 
161 Cortical F-actin regulates somato-dendritic exocytosis; F-actin polymerization inhibits and F-actin 
162 depolymerisation increases somato-dendritic secretion from MNCs (48). Presumably, F-actin 
163 depolymerisation increases access to the plasma membrane and this process might account for the 
164 requirement for a sustained increase in intracellular calcium to trigger somato-dendritic secretion, 
165 since calcium causes F-actin depolymerisation. Unlike synaptic transmission, there does not appear to 
166 be any specific structure on the soma or dendrites that is specialised for somato-dendritic secretion 
167 (49), although it remains to be determined whether there are regions of the cortical F-actin network 
168 that are more readily depolymerised to allow dense core vesicles preferential access to the plasma 
169 membrane at specific sites for secretion. 
170 Exocytosis can occur once the dense core vesicles reach the plasma membrane, which requires 
171 exocytotic machinery. The involvement of the soluble N-ethylmaleimide-sensitive factor attachment 
172 receptor (SNARE) complex in exocytosis from axon terminals is well established (50). While less 
173 well characterised, it appears that somato-dendritic secretion is also mediated by SNARE proteins. 
174 MNCs express SNARE proteins (51), however, while vesicle-associated membrane protein-2 
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175 (VAMP-2) and synaptosomal-associated protein 25 (SNAP-25) are both expressed in the axon 
176 terminals (52, 53), they are not expressed in the somata or dendrites of MNCs (54). Hence, the suite 
177 of SNARE complex proteins for somato-dendritic exocytosis likely differs from that for axon terminal 
178 secretion from MNCs. 
179 Stimulation of somato-dendritic secretion by neurotransmitters, peptides and hormones
180 Noradrenergic afferents from the ventrolateral medulla (VLM) A1 cell group and the nucleus of the 
181 tractus solitarius (NTS) A2 cell group make prominent projections to MNCs (2). NTS noradrenergic 
182 afferents are activated during birth and lactation (55) as part of the Ferguson reflex (56), and 
183 noradrenaline facilitates somato-dendritic oxytocin secretion in late pregnancy and lactation (57-59). 
184 Oxytocin also increases noradrenaline secretion within the SON (60), which presumably establishes a 
185 local positive feedback loop that reinforces oxytocin MNC excitation and promotes oxytocin secretion 
186 into the circulation to trigger uterine contractions during birth and milk ejection during lactation 
187 (Figure 3).
188 Proopiomelanocortin (POMC) afferents from the ARC project to the SON and PVN, particularly to 
189 regions of the SON and PVN that are enriched in oxytocin MNCs (61). POMC neurones secrete α-
190 melanocyte stimulating hormone (α-MSH), which acts on melanocortin-4 (MC4-R) receptors in the 
191 SON and PVN (62). While α-MSH inhibits oxytocin secretion into the circulation, it increases 
192 somato-dendritic oxytocin secretion (37, 63). MC4-R activation increases intracellular calcium in 
193 oxytocin MNCs to trigger somato-dendritic oxytocin secretion as well as endocannabinoid secretion, 
194 which inhibits the activity of the MNCs to reduce axonal oxytocin secretion into the blood (37, 63). 
195 Remarkably, α-MSH inhibition of oxytocin MNC activity is lost in mid-pregnancy (62), but it has yet 
196 to be determined whether this represents a switch from pre-pregnancy inhibition to stimulation during 
197 lactation, as is seen for prolactin effects on oxytocin MNCs (64). Furthermore, it is not known 
198 whether α-MSH effects on somato-dendritic oxytocin secretion change in pregnancy and lactation.
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199 In addition to neurotransmitters, other hormones can also trigger somato-dendritic secretion from 
200 MNCs. The orexigenic hormone, ghrelin is synthesised by oxyntic cells in the gastric mucosa, but not 
201 in the brain (65). Central ghrelin administration increases vasopressin secretion into the circulation via 
202 activation of neuropeptide Y neurones (66). In addition, ghrelin stimulates somato-dendritic 
203 vasopressin secretion, which increases adenosine triphosphate (ATP) release from astrocytes to 
204 increase presynaptic GABA release onto the vasopressin MNCs (67) (Figure 4).
205 Autocrine/paracrine modulation of vasopressin magnocellular neurosecretory cell activity
206 The effects of vasopressin, oxytocin and other neurotransmitters and neuromodulators secreted from 
207 the somata and dendrites of MNCs can be broadly categorised as autocrine, regulating the activity of 
208 the MNC from which secretion occurs, and paracrine, regulating the activity of neighbouring neurons, 
209 including other neuronal populations. 
210 V1aR and V1b receptors (V1bR) are expressed in the membranes of vasopressin-containing dense core 
211 vesicles (68) and are presumably inserted into the plasma membrane during somato-dendritic 
212 vasopressin secretion. Hence, vasopressin receptors newly trafficked to the plasma membrane will be 
213 exposed to high concentrations of vasopressin to underpin activity-dependent autocrine feedback 
214 regulation of vasopressin MNC activity. 
215 Vasopressin MNCs express a range of activity patterns under basal conditions; some are silent 
216 throughout recordings, some display irregular activity, some are continuously-active (typically at 
217 ~6 spikes s-1), and some display rhythmic ‘phasic’ firing (69). Phasic firing is characterised by 
218 bursts of activity that last more than 15 s, after which bursts stop randomly (70). Each burst is 
219 followed by inactivity for at least 10 s, after which the next burst starts randomly (70). At burst 
220 onset, vasopressin MNCs can reach firing rates of ~15 – 25 spikes s-1 for the first 5 – 10 s, before 
221 spike frequency adaptation occurs to a steady-state firing rate of ~ 6 spikes s-1 for the remainder of 
222 the burst (71, 72).
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223 Of the different activity patterns recorded in vasopressin MNCs, phasic bursting is the most efficient 
224 pattern for vasopressin secretion into the circulation because vasopressin secretion is maximal at ~13 
225 spikes s-1 (73, 74), which is typically only achieved by phasically firing MNCs and only during the 
226 first 5 – 10 s of each phasic burst. Vasopressin secretion from the posterior pituitary gland rapidly 
227 fatigues during continuous stimulation, but this fatigue is reversed when stimulation is stopped for a 
228 few tens of seconds (75). Hence, vasopressin MNCs firing continuously at high frequency do not 
229 secrete as much vasopressin into the circulation as do phasic MNCs firing at the same frequency 
230 because the silent periods between bursts in phasic MNCs reset the system for efficient vasopressin 
231 secretion at the onset of the next burst, when the typical firing frequency is again in the range that is 
232 most efficient for vasopressin secretion. The importance of phasic activity for efficient vasopressin 
233 secretion into the circulation is highlighted by the changes in activity patterning that occur under 
234 chronically stimulated conditions, such as prolonged osmotic stimulation. While burst duration does 
235 increase during shorter periods of stimulation, prolonged osmotic stimulation leads to an increase in 
236 firing rate within bursts while the burst duration and inter-burst interval remain similar to those seen 
237 under basal conditions (76-79). 
238 V1aR antagonists consistently increase the activity of phasic MNCs when administered into the 
239 SON (80), suggesting that somato-dendritic vasopressin mediates feedback inhibition of 
240 vasopressin MNCs via V1aR activation (Figure 5). This feedback inhibition likely involves direct 
241 autocrine actions on the MNC that secretes vasopressin because V1aR activation reduces excitatory 
242 postsynaptic potential amplitude in vasopressin MNCs (81). However, autocrine activation of 
243 V1aRs does not mediate autoregulation of vasopressin MNC activity alone because vasopressin 
244 also increases inhibitory postsynaptic potential frequency (82) via stimulation of astrocytic 
245 adenosine triphosphate (ATP) release, which acts as a gliotransmitter at P2X receptors on 
246 presynaptic GABA neurones to increase GABA release (67). Hence, somato-dendritic vasopressin 
247 secretion appears to contribute to the generation of phasic activity in vasopressin MNCs via a 
248 combination of autocrine actions on the MNC from which secretion occurs and paracrine actions 
249 on nearby cells that modulate the activity of the MNC from which secretion occurs.
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250 While V1aR activation mediates autocrine and paracrine inhibition of phasic activity, local 
251 application of exogenous vasopressin was first reported to inhibit highly active phasic MNCs and 
252 stimulate weakly active phasic MNCs (83). Vasopressin MNCs also express V1bR (68), and while 
253 it has yet to be determined whether V1bR activation also contributes to autocrine regulation of 
254 vasopressin MNCs, it might underpin the excitatory effects of vasopressin evident in weakly active 
255 vasopressin MNCs. Regardless of the vasopressin excitation of weakly active phasic MNCs 
256 (perhaps via V1bR), such an action of endogenous vasopressin would presumably increase 
257 peripheral vasopressin secretion to cause robust vasoconstriction that is not present under basal 
258 conditions (84). Hence, it seems likely that any contribution of somato-dendritic vasopressin 
259 secretion to peripheral vasopressin secretion by feedback excitation is overridden by the V1aR-
260 mediated feedback inhibition.
261 While, somato-dendritic vasopressin secretion functions as a negative feedback regulator of 
262 vasopressin MNC activity at the single cell level, the important output of the system is overall 
263 hormone secretion, which depends on the integrated activity of the MNCs at a population level 
264 (10). Some of the earliest work on somato-dendritic secretion showed that osmotic stimulation of 
265 vasopressin MNCs increases vasopressin levels in the circulation before levels increase in the SON 
266 (85), which is consistent with somato-dendritic vasopressin secretion acting as a negative feedback 
267 regulator of vasopressin MNC activity at a population level to modulate overall vasopressin 
268 secretion into the circulation.
269 Autocrine/paracrine modulation of vasopressin magnocellular neurosecretory cell activity by 
270 co-secreted transmitters
271 Vasopressin MNCs also synthesise and secrete a number of other neurotransmitters and 
272 neuromodulators, including apelin (86), ATP (87), carbon monoxide (CO) (88), dynorphin (89), 
273 endocannabinoids (90-92), galanin (93), neuroendocrine regulatory peptides (NERPs) (94, 95), 
274 nitric oxide (NO) (96), PACAP (97) and secretin (13). 
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275 Most neuropeptides synthesised by MNCs are packaged within the same dense core vesicles as 
276 either vasopressin or oxytocin. However, apelin and galanin are differentially packaged in 
277 vasopressin MNCs. Apelin is packaged in dense core vesicles that do not contain vasopressin (98). 
278 While galanin is also packaged in some dense core vesicles that also contain vasopressin, it is also 
279 packaged in others that do not contain vasopressin and some dense core vesicles contain 
280 vasopressin but no galanin. Presumably, differential packaging in dense core vesicles might allow 
281 for secretion of separate pools that contain vasopressin or their co-expressed neuropeptides. Indeed, 
282 dense core vesicles containing galanin alone are trafficked to the dendrites while those that contain 
283 only vasopressin are trafficked to the axon terminals in the posterior pituitary gland (93). 
284 Vasopressin MNCs express apelin receptors (APJ receptors) (99) and centrally-administered apelin 
285 inhibits vasopressin MNCs (86) to decrease basal vasopressin secretion (86, 100). However, systemic 
286 apelin administration increases vasopressin secretion (101) and chronic infusion of apelin into the 
287 PVN also increases vasopressin secretion (102). Furthermore, administration of apelin directly into 
288 the SON increases the activity of phasic MNCs (and presumably vasopressin secretion into the 
289 circulation) via non-specific cation channel activation, but reduces somato-dendritic vasopressin 
290 secretion (99), which presumably weakens vasopressin-mediated autoregulation to disinhibit and thus 
291 further excite vasopressin MNCs.
292 Vasopressin MNCs express galanin receptor-1 (Gal-R1) on their somata and dendrites (103). While 
293 centrally-administered galanin increases vasopressin secretion into the circulation in vivo (104, 105), 
294 it inhibits vasopressin secretion from isolated neurohypophyses or hypothalamo-neurohypophysial 
295 explants in vitro (106), suggesting that the direct effects of galanin are inhibitory, despite the reduced 
296 somato-dendritic vasopressin secretion. Indeed, galanin directly inhibits vasopressin MNCs in vitro by 
297 inducing hyperpolarization and reducing the slow afterdepolarisation (sADP) (107), which is a 
298 prominent excitatory post-spike potential in vasopressin MNCs (108). Galanin also reduces EPSC 
299 frequency (109), suggesting that it might also have paracrine effects after somato-dendritic secretion 
300 by retrograde inhibition of excitatory synaptic transmission.
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301 Similarly to vasopressin receptors, κ-opioid receptors (KORs) are expressed in the membranes of 
302 vasopressin-containing dense core vesicles (110) and unlike apelin and galanin, the endogenous 
303 opioid peptide (EOP) ligand for KORs, dynorphin, is packaged with vasopressin in the same dense 
304 core vesicles (111). Hence, KORs newly-trafficked to the vasopressin MNC plasma membrane will be 
305 exposed to high concentrations of dynorphin upon somato-dendritic secretion of dense core vesicles.
306 KOR agonists inhibit vasopressin MNCs in vivo (69, 112) and in vitro (113, 114). More importantly, 
307 antagonism of SON KORs increases burst duration in phasic MNCs under basal conditions in vivo 
308 (69, 70, 115) and in vitro (70, 116), showing that an endogenous KOR agonist inhibits phasic bursts. 
309 Phasic bursts are underpinned by the summation of sADPs to form a plateau potential that maintains a 
310 depolarised membrane potential to sustain further firing during bursts, and KOR activation causes 
311 activity-dependent sADP inhibition (116) to progressively decrease the plateau potential amplitude, 
312 which eventually leads to burst termination (70). Furthermore, KOR desensitisation prevents phasic 
313 activity in vasopressin MNCs, even when intensely stimulated (69). Hence, an endogenous KOR 
314 agonist inhibits phasic MNCs by autocrine inhibition of the sADP in the MNC from which dynorphin 
315 is secreted and this inhibition appears to be necessary for the expression of phasic activity by 
316 vasopressin MNCs.
317 In addition to sADP inhibition, KOR agonists reduce EPSP and IPSP amplitude (114, 117) and the 
318 delayed rectifier potassium current (118), while increasing the transient A-type potassium current 
319 (118) in vasopressin MNCs, although it has yet to be established whether these effects also contribute 
320 to the generation of phasic activity. 
321 While KOR activation inhibits continuously-active vasopressin MNCs, KOR antagonism does not 
322 affect continuously-active vasopressin MNCs, even when they are strongly excited (76). Hence it 
323 appears that continuously-active vasopressin MNCs express KORs but do not release sufficient 
324 dynorphin to affect activity. Some vasopressin MNCs display irregular activity and these MNCs 
325 appear to be even more strongly excited by KOR antagonism than phasic MNCs (76). Taken together, 
326 this pattern-dependent sensitivity to KOR inhibition suggests that somato-dendritic dynorphin 
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327 secretion might determine the firing pattern of vasopressin MNCs and that transitions between firing 
328 patterns in individual vasopressin MNCs might result from changes in somato-dendritic dynorphin 
329 secretion (119)
330 MNCs also express receptors for pituitary adenylate cyclase-activating polypeptide (PACAP), which 
331 they also synthesise and secrete (97). PACAP increases somato-dendritic vasopressin secretion (120) 
332 by a direct depolarisation through activation of non-specific cation channels (121). 
333 Neuroendocrine regulatory peptides (NERPs) 1 – 3 are packaged with vasopressin in the SON and 
334 PVN (94, 95). NERP-1 has paracrine effects on vasopressin MNC activity by retrograde inhibition of 
335 excitatory synaptic transmission whereas paracrine inhibition of vasopressin MNCs by NERP-2 is 
336 mediated by activation of upstream GABAergic interneurones that inhibit glutamatergic neurones that 
337 project to vasopressin MNCs (122). In contrast to NERPs 1 and 2, NERP-3 stimulates vasopressin 
338 secretion from the isolated posterior pituitary gland (95).
339 Vasopressin MNCs express secretin receptors and central secretin administration increases plasma 
340 vasopressin concentrations (13), suggesting that somato-dendritic secretin might stimulate systemic 
341 vasopressin secretion. However, secretin is also released from afferent inputs to the SON (123) and 
342 systemic secretin administration excites vasopressin (and oxytocin) MNCs via noradrenergic 
343 afferent inputs (124), suggesting that its actions might be mediated by afferent inputs rather than 
344 somato-dendritic secretion. While its role as a neurohypophysial hormone has not yet been 
345 definitively established, secretin is expressed in the posterior pituitary gland (13) and increases 
346 insertion of aquaporin-2 into the luminal membrane of the kidney to increase water reabsorption 
347 (125). Hence, secretin synthesised by vasopressin MNCs might act as a neurohypophysial hormone 
348 after secretion from the posterior pituitary gland rather than as an autoregulatory factor secreted 
349 from the somata and dendrites. 
350 Vasopressin MNCs express P2X and P2Y receptors (126 , 127) and injection of ATP into the SON 
351 induces antidiuresis (128). ATP is packaged in vasopressin dense core vesicles (87). ATP depolarises 
352 MNCs (129) and increases vasopressin secretion from hypothalamo-neurohypophysial explants (130). 
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353 ATP also increases glutamate and GABA release at synapses on MNCs (131). Hence, somato-
354 dendritic ATP secretion might excite vasopressin MNCs by autocrine actions on the MNC from 
355 which it is secreted and paracrine actions on afferent inputs to the MNC from which it is secreted. 
356 However, MNCs are also excited by ATP released by astrocytes as a gliotransmitter (67, 132) as well 
357 as by ATP released from noradrenergic afferent inputs (133).
358 While somato-dendritic ATP secretion might modulate vasopressin MNC activity, ATP is rapidly 
359 catabolised to adenosine in the extracellular space (134). Vasopressin MNCs express adenosine A1 
360 and A2A receptors (135) and A1 receptor antagonism excites phasic MNCs in vivo, but does not 
361 affect the firing rate of continuously-active vasopressin MNCs (136). A1 receptor antagonism reduces 
362 activity-dependent inhibition of EPSCs and IPSCs (137) as well as activity-dependent enhancement of 
363 the medium afterhyperpolarisation (mAHP) in vasopressin MNCs (138). mAHP activation induces 
364 spike frequency adaptation at the onset of phasic bursts (139) and so endogenous adenosine 
365 enhancement of the mAHP increases spike frequency adaptation, thereby shortening bursts in phasic 
366 MNCs (136). While A2 receptor activation depolarises MNCs to increase firing rate (135), 
367 vasopressin MNCs are inhibited when adenosine uptake is blocked. Hence, the overall effect of 
368 endogenous adenosine appears to be vasopressin MNC inhibition (140).
369 In addition to somato-dendritic exocytosis, vasopressin MNCs also release the gaseous transmitters, 
370 NO and carbon monoxide (CO), by diffusion after synthesis by NO synthase (NOS) and haem-
371 oxygenase I, respectively. NO inhibits vasopressin MNCs (141, 142) by increasing IPSC amplitude 
372 and frequency (142, 143), whereas CO excites vasopressin MNCs (88).
373 Somato-dendritic modulation of vasopressin MNC activity appears to impact hormone secretion 
374 into the circulation through a complex interplay of excitatory (apelin, PACAP, ATP, NO and 
375 perhaps secretin) and inhibitory (galanin, dynorphin, NERPs, adenosine and CO) feedback that 
376 might fine tune the activity of individual MNCs to prevent any one MNC bearing too much of the 
377 secretory load for too long under basal conditions. It seems counter-intuitive that the autoregulatory 
378 effects of (at least some) co-secreted transmitters appear greater than that of vasopressin itself, 
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379 which is secreted in vastly greater quantities. Perhaps the autoregulatory effects of co-secreted 
380 transmitters are magnified by activation of both paracrine and autocrine mechanisms. In addition, it 
381 is possible that vasopressin’s major role is paracrine inhibition of the population as a whole to 
382 prevent over-secretion of vasopressin into the circulation in response to perturbations of body fluid 
383 balance and/or blood pressure/volume.
384 Autocrine/paracrine modulation of oxytocin magnocellular neurosecretory cell activity
385 Similar to somato-dendritic vasopressin secretion, somato-dendritic oxytocin secretion also has 
386 autocrine and paracrine actions that modulate oxytocin MNC activity. In contrast to vasopressin, the 
387 autocrine and paracrine effects of oxytocin are arranged in series rather than in parallel; somato-
388 dendritic oxytocin secretion activates oxytocin receptors (OTRs) on oxytocin MNCs to increase 
389 intracellular calcium, which has various actions including the release of endocannabinoids that cause 
390 retrograde inhibition of excitatory synaptic transmission under basal conditions (90). While the 
391 oxytocin-stimulated retrograde endocannabinoid suppression of excitatory synaptic input is expected 
392 to inhibit oxytocin MNCs (Figure 6), the best characterised effects of somato-dendritic oxytocin 
393 secretion is excitation, but only under specific (patho)physiological conditions. Hence, it has been 
394 proposed that endocannabinoid inhibition might occur over a longer timescale than autocrine effects 
395 of oxytocin to shape activity patterning in oxytocin MNCs during birth and lactation (144), but it has 
396 yet to be established whether this occurs in vivo. Alternatively, the excitatory effects of oxytocin 
397 might involve a switch from endocannabinoid inhibition to excitation during pregnancy, perhaps by 
398 enhanced expression/activation of excitatory transient receptor potential vanilloid-1 channels (145) 
399 for which the endocannabinoid, anandamide, is an endogenous ligand (146). Additionally, spillover of 
400 the endocannabinoid 2-arachidonoylglycerol from glutamate onto GABA synapses and a resulting 
401 suppression of inhibitory synaptic input has been observed in MNCs following glial retraction 
402 induced by salt loading (91). This endocannabinoid spillover could also occur with glial retraction 
403 during parturition and lactation to reduce inhibitory synaptic transmission, although this remains to be 
404 determined. Finally, it is also possible that oxytocin-stimulated endocannabinoid retrograde 
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405 modulation of excitatory and inhibitory synapses might be overridden by changes in the postsynaptic 
406 properties of oxytocin MNCs (147, 148), increased excitatory afferent inputs (149-153), or a switch in 
407 GABA signalling from inhibitory to excitatory, or less inhibitory, during pregnancy (64, 154).
408 Oxytocin MNCs typically exhibit continuous activity at ~1 – 5 spikes s-1 under basal conditions to 
409 maintain circulating oxytocin concentrations of ~1 – 3 pg ml-1, with higher concentrations during 
410 sleep (2). However, oxytocin is best known for its stimulation of rhythmic uterine contraction 
411 during birth and of episodic milk ejection during suckling. Uterine contractions and mammary duct 
412 contraction each occur at intervals of several minutes and each contraction is triggered by a 
413 coordinated, high frequency burst of activity across the population of oxytocin MNCs (155) to 
414 secrete a discrete pulse of oxytocin into the circulation, which transiently increases intrauterine 
415 pressure during birth (156) and intramammary pressure during suckling (157). 
416 Somato-dendritic oxytocin secretion increases immediately preceding each burst of activity in 
417 lactating rats (158) and bursts are blocked by OTR antagonist administration (159), as is the rise in 
418 somato-dendritic oxytocin secretion (160), suggesting that somato-dendritic oxytocin secretion is 
419 required for bursts to occur. However, the mechanisms by which somato-dendritic oxytocin 
420 secretion promotes burst firing in oxytocin MNCs are not fully understood and it is likely not the 
421 only contributor; synchronised volleys of EPSPs (161), rebound depolarization after bursts of 
422 IPSPs (162) and enhancement of the sADP (147, 163) have all been proposed to trigger or sustain 
423 firing during bursts in oxytocin MNCs. 
424 In brain slices from male rats that do not normally fire bursts, α1-adrenoceptor activation in low 
425 calcium can induce bursts in oxytocin MNCs reminiscent of those seen during birth and milk ejection 
426 (164). Hence, noradrenergic inputs might trigger bursts. Consistent with this hypothesis, 
427 noradrenergic innervation of oxytocin MNCs is increased in late pregnancy (152) and these afferent 
428 inputs are activated during birth (55) to increase noradrenaline release into the SON (165). 
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429 Noradrenergic stimulation of bursts in oxytocin MNCs might be mediated by somato-dendritic 
430 oxytocin release because noradrenergic receptor stimulation is required for suckling-induced somato-
431 dendritic oxytocin release (58), which might be part of a positive feedback loop that builds towards 
432 bursts during continuous suckling. Indeed, burst-like activity can also be induced in virgin rats in vivo 
433 by coordinated activation of neighbouring oxytocin MNCs, which induces priming of somato-
434 dendritic dense core vesicles for subsequent secretion (28). Once primed, high-frequency electrical 
435 stimulation induces bursting in oxytocin MNCs of virgin rats (28). Hence, continuous suckling might 
436 trigger tonic noradrenaline release onto oxytocin MNCs that triggers increasing somato-dendritic 
437 oxytocin secretion, which could prime further somato-dendritic oxytocin secretion until a tipping-
438 point is reached to induce each burst.
439 In addition to facilitating burst firing in individual oxytocin MNCs, somato-dendritic oxytocin 
440 secretion might also help coordinate the timing of bursts across the population of oxytocin MNCs. 
441 Oxytocin injection into one SON increases the frequency of milk ejection bursts in the contralateral 
442 SON (166). Oxytocin MNCs have 1 – 3 dendrites (148) that are normally separated from 
443 neighbouring dendrites by astrocytic processes. However, in late pregnancy and lactation, astrocytes 
444 withdraw their processes from between oxytocin MNC dendrites, which then form bundles of ~ 10 
445 closely apposed dendrites (167, 168). A mathematical model in which oxytocin MNCs send each 
446 dendrite to different dendritic bundles to form a sparse network of interactions emulates burst firing in 
447 which each burst is initiated randomly at any of the dendritic bundles and spreads rapidly through the 
448 oxytocin MNC population (144). 
449 However, this model does not account for coordination of bursts across the bilateral SONs and PVNs 
450 which might be mediated by noradrenergic inputs that project bilaterally to the SON (169). Indeed, 
451 sectioning the optic chiasm or mammillary body disrupts co-ordination of bursts between oxytocin 
452 MNCs in the left and right SON, suggesting that burst coordination across the magnocellular nuclei 
453 involves projections through these areas (169, 170). Furthermore, the perinuclear zone that lies 
454 immediately dorsal to the SON sends prominent projections to the SON (171) and PVN (172, 173) 
455 that might also contribute to coordination of bursts across the four main magnocellular nuclei. 





























































For Peer Review Only
19
456 Autocrine/paracrine modulation of oxytocin magnocellular neurosecretory cell activity by co-
457 secreted transmitters 
458 Oxytocin MNCs also synthesise other transmitters that are likely secreted from their somata and 
459 dendrites, but the effects of these co-transmitters are not as well characterised as for those released 
460 from vasopressin MNCs. 
461 Oxytocin MNCs express µ-opioid receptors (MORs) and KORs (174, 175), and MOR or KOR 
462 activation inhibits oxytocin MNCs (69, 176). While oxytocin MNCs synthesise µ- and κ-EOPs 
463 (177, 178), neither MOR nor KOR antagonists affect the activity of oxytocin MNCs in vivo (69, 
464 179). Hence it appears that if EOPs undergo somato-dendritic secretion with oxytocin, they do not 
465 modulate oxytocin MNC activity to any appreciable extent under basal conditions. MOR-mediated 
466 EOP inhibition of somato-dendritic oxytocin secretion and oxytocin MNC activity is increased in 
467 late pregnancy (180), but this modulation is likely to be mediated by afferent inputs (181). 
468 By contrast to the central actions of MOR activation, KOR activation appears to restrain secretion 
469 into the bloodstream at the posterior pituitary gland (182) and this effect also increases in late 
470 pregnancy (183). KOR restraint of oxytocin secretion might build up stores of oxytocin for birth 
471 and lactation and might potentiate secretion during bursts because KORs are desensitised on the 
472 day of birth (184, 185).
473 Oxytocin MNC dense core vesicles also contain ATP, which is presumably secreted along with 
474 oxytocin from the somata and dendrites. Co-secreted ATP does not modulate oxytocin MNC 
475 activity via adenosine receptor activation (136), it might excite oxytocin MNC via P2X receptor 
476 activation (130, 131).
477 Oxytocin MNCs also express NOS (96) and NO appears to restrain the activity of oxytocin MNCs, 
478 particularly under stimulated conditions (186, 187), suggesting that NO is an inhibitory 
479 autocrine/paracrine modulator of oxytocin MNC activity. 
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480 Remarkably, chronic MOR activation by the opioid alkaloid agonist, morphine, (but not EOPs 
481 (188)) induces tolerance and dependence in oxytocin MNCs (189). Tolerance is revealed as loss of 
482 inhibition to acute administration of morphine (176) and dependence is revealed by a sustained 
483 hyperexcitation upon withdrawal of chronic morphine administration (112). Somato-dendritic 
484 oxytocin secretion is increased during morphine withdrawal and OTR antagonism reduces 
485 morphine withdrawal-induced excitation of oxytocin MNCs (190). Hence, somato-dendritic 
486 oxytocin secretion appears to contribute to morphine withdrawal-induced excitation of oxytocin 
487 MNCs, although the mechanism by which it does so has yet to be identified. 
488 Paracrine modulation of parvocellular paraventricular nucleus neurone activity by somato-
489 dendritic secretion from magnocellular neurosecretory cells 
490 While the SON essentially contains only MNCs (and glia and cells of the vasculature), the PVN also 
491 contains parvocellular neurones. Parvocellular neurones are sub-divided by their projections and 
492 functions: neurosecretory parvocellular neurones project to the hypothalamic median eminence, where 
493 they secrete hormones into the hypophysial portal blood vessels to control hormone secretion from the 
494 anterior pituitary gland; preautonomic parvocellular neurones project to the brainstem and spinal cord 
495 to modulate parasympathetic and sympathetic nervous system activity (191, 192); the remaining 
496 parvocellular neurones project to various brain areas to modulate behaviour.
497 It has long been hypothesised that somato-dendritic secretion from MNCs modulates the activity of 
498 parvocellular neurones but only recently has definitive evidence to support this hypothesis been 
499 generated for somato-dendritic vasopressin (38, 193, 194). For paracrine effects on other neuronal 
500 phenotypes to occur, first vasopressin (or oxytocin) must diffuse through the parenchyma to reach 
501 other neurones. The effective diffusion distance for somato-dendritic vasopressin was determined 
502 under basal conditions using Chinese hamster ovary cells transfected with human V1aRs and a 
503 calcium indicator to generate biosensor ‘sniffer’ cells with a threshold detection level of 0.5 nM and 
504 an EC50 of 7.2 nM for vasopressin (38). Using sniffer cells that were dispersed over the PVN in 
505 hypothalamic slices, it was shown that activation of an individual MNC induces sufficient somato-
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506 dendritic vasopressin secretion to induce intracellular calcium increases for tens of seconds in sniffer 
507 cells over 100 μm from the soma of the activated MNC (38). Similar results were seen using HEK-
508 293 sniffer cells in the SON (194). Hence, somato-dendritic vasopressin release from an individual 
509 MNC diffuses through the PVN at sufficient concentration to activate V1aRs expressed on 
510 parvocellular neurone somata or dendrites under basal conditions (38, 193). Remarkably, astrocytes 
511 withdraw their processes from between MNCs when chronically stimulated (167, 168, 195, 196), 
512 which reduces the tortuosity of the extracellular space and likely increases the effective diffusion 
513 distance for somato-dendritic vasopressin and oxytocin through the parenchyma (197).
514 Some preautonomic parvocellular neurones project to the rostral ventrolateral medulla (RVLM) in the 
515 brainstem, which projects to sympathetic ganglia to regulate sympathetic nerve activity (198). 
516 RVLM-projecting parvocellular neurones express V1aRs and their dendrites are intermingled with 
517 vasopressin MNC somata and dendrites in the PVN (193). Hence, the architecture is in place to 
518 provide for somato-dendritic vasopressin modulation of autonomic function by paracrine modulation 
519 of preautonomic neurones within the PVN (Figure 7). Activation of individual vasopressin MNCs by 
520 uncaging NMDA increases action potential firing in RVLM-projecting parvocellular neurones beyond 
521 100 μm from the activated MNC (193) and this activation is much more potent than that elicited by 
522 action potential firing alone (38), suggesting that dendritic NMDARs might be a main driver of 
523 somato-denritic secretion. The responses of RVLM-projecting parvocellular neurones to vasopressin 
524 MNC activation occur after a delay of several seconds, are blocked by superfusion of a V1aR 
525 antagonist and are enhanced by a peptidase inhibitor (193). Most importantly, the depolarisation of 
526 RVLM-projecting parvocellular neurones in response to vasopressin MNC activation is not affected 
527 by blockade of action potential firing with tetrodotoxin. Taken together, the data demonstrate that the 
528 excitation of RVLM-projecting parvocellular neurones is mediated by diffusion of somato-dendritic 
529 vasopressin through the extracellular space of the PVN.
530 Given that activation of an individual vasopressin MNC can excite preautonomic neurones within a 
531 radius of at least 100 μm, it appears likely that somato-dendritic secretion from the population of 
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532 MNCs, as occurs in vivo, could function as a population-to-population signal to recruit preautonomic 
533 neurones as a whole. Indeed, administration of a V1aR antagonist alone reduces preautonomic 
534 neurone activity and the more active the MNC, the more effective is the antagonist at reducing 
535 preautonomic neurone activity (193), suggesting that preautonomic neurones are under tonic 
536 modulation by vasopressin MNCs to coordinate the humoral (circulating vasopressin) and neuronal 
537 (sympathetic nerve activity) responses to changes in body fluid balance and to pathophysiological 
538 conditions, such as hypertension, myocardial infarction and chronic heart failure. 
539 Hyperosmolality increases vasopressin secretion into the circulation by MNCs and increases renal 
540 sympathetic nerve activity, both of which increase water retention to protect body fluid balance. The 
541 mechanisms that underpin these responses to hyperosmolality are thoroughly reviewed elsewhere 
542 (199, 200). While these mechanisms occur in parallel, somato-dendritic vasopressin secretion likely 
543 coordinates the responses because intracarotid infusion of hyperosmotic saline causes a dose-
544 dependent increase in renal sympathetic nerve activity that is accompanied by increased somato-
545 dendritic vasopressin secretion, and bilateral injection of a V1aR antagonist into the PVN abolishes 
546 the renal sympathetic nerve activation (193). Hence, it appears that somato-dendritic vasopressin 
547 secretion coordinates the humoral and neuronal responses to increased osmolality.
548 PVN-driven sympathoexcitation is a key pathophysiological mechanism in hypertension (201, 202), 
549 acute myocardial infarction (192, 203) and heart failure (204, 205) that contributes to morbidity and 
550 mortality (206). Vasopressin MNCs are activated in hypertension (207, 208), acute myocardial 
551 infarction (209) and heart failure (210, 211). While the increased circulating vasopressin levels 
552 contribute directly to detrimental myocardial effects (212, 213), increased vasopressin MNC activity 
553 probably also increases somato-dendritic vasopressin secretion to contribute to the pathophysiological 
554 sympathoexcitation via activation of PVN preautonomic neurones.
555 While less well established than for vasopressin effects on preautonomic neurones, it appears that 
556 somato-dendritic oxytocin secretion might also modulate the activity of a neighbouring population of 
557 neurones within the PVN, corticotrophin-releasing hormone (CRH) neurones. Stress-induced CRH 
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558 secretion stimulates adrenocorticotrophic hormone secretion from the anterior pituitary gland (214) 
559 that, in turn, increases adrenal corticosteroid secretion to mediate the body’s response to the stressor. 
560 CRH neurones express mRNA for OTRs (215) and oxytocin inhibits EPSC frequency, but not 
561 amplitude, in CRH neurones (216). Oxytocin MNC and CRH neurone dendrites are intermingled 
562 within the PVN (216), allowing for dendro-dendritic interactions between the two populations. Hence, 
563 somato-dendritic oxytocin might suppress CRH neurone excitability by presynaptic inhibition of 
564 excitatory synaptic inputs to reduce activation of the stress axis. However, OTR antagonism has no 
565 effect on CRH neurones in brain slices (216), suggesting that, unlike vasopressin modulation of 
566 preautonomic neurone activity, there is no OTR tone on CRH neurones, at least under in vitro basal 
567 conditions.
568 Paracrine modulation of arteriolar vasoconstriction in the supraoptic nucleus by somato-
569 dendritic secretion from magnocellular neurosecretory cells
570 Classically, neuronal activity is thought to dilate arterioles and thereby increase local cerebral 
571 blood flow to meet the metabolic demands of active brain areas; this ‘neurovascular coupling’ is 
572 generally accepted to result from glutamatergic synaptic transmission that evokes release of 
573 vasoactive substances from neurones and astrocytes to relax vascular smooth muscle cells (217). 
574 However, vascular smooth muscle cells express V1aRs, providing a target for somato-dendritic 
575 vasopressin, at least within the SON and PVN. Vasoconstriction can be elicited in SON arterioles 
576 by stimulation of an individual vasopressin MNC, an effect that is blocked by V1aR antagonism 
577 (218) (Figure 7). Consistent with its effects on preautonomic neurones, somato-dendritic 
578 vasopressin can induce responses in arterioles beyond 100 μm from the activated MNC under basal 
579 conditions (218). Importantly, this V1aR-mediated vasoconstriction is over-ridden in hyperosmotic 
580 conditions by parallel release of NO, which causes vasodilation of local arterioles (218). 
581 Presumably the NO-induced vasodilation increases blood flow through the SON when increased 
582 vasopressin MNC activity is required to protect from further fluid loss and maintain blood pressure 
583 in the general circulation through vasopressin secretion from the posterior pituitary gland.
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584 Paracrine modulation of neuronal activity beyond the paraventricular nucleus by somato-
585 dendritic secretion from magnocellular neurosecretory cells
586 While paracrine modulation of parvocellular neurones within the PVN by somato-dendritic secretion 
587 from MNCs is now well characterised, it has yet to be definitively established whether neuropeptides 
588 secreted from MNC somata and dendrites can affect the activity of neurones outside the PVN. 
589 Nevertheless, there is some evidence that somato-dendritic oxytocin might act on neurones in brain 
590 areas relatively close to the SON and/or PVN, particularly for brain areas that receive little or no 
591 axonal projections from MNCs or from vasopressin or oxytocin parvocellular neurones. 
592 The central effects of the primary anorexigenic hormone, leptin, are mediated by oxytocin, at least in 
593 part (219). Leptin is sensed by ARC POMC neurones that, as described above, project to the SON and 
594 PVN (61), where they secrete α-MSH to activate MC4-Rs (62) and thereby increase somato-dendritic 
595 oxytocin secretion (63, 220). Oxytocin inhibition of food intake is mediated, in part, by the 
596 ventromedial hypothalamus (VMH) because oxytocin injection into the VMH decreases food intake 
597 that is driven by energy balance rather than palatability (221). While OTRs are highly expressed in the 
598 VMH (222), there are essentially no oxytocin MNC axons in the VMH (219). Given that vasopressin 
599 released from a single MNC can activate cells over 100 μm from the MNC soma from which it is 
600 secreted (38, 193) and the VMH is situated roughly between the SON and PVN, it is possible that 
601 somato-dendritic oxytocin release from MNCs could diffuse through the parenchyma in sufficient 
602 quantities to activate OTRs in the VMH, which have nanomolar affinity for oxytocin (223). It is also 
603 possible that OTR-expressing astrocytes in the SON and PVN could expand the spatial domain of the 
604 dendritically released oxytocin signalling by relaying the signals through astrocytic networks, as has 
605 been reported for vasopressin release from vasopressin MNC dendrites (67) and CRH neurone 
606 dendrites (224).
607 While oxytocin MNCs inhibit fear responses via axon collaterals to the CeA (17), it appears likely 
608 that SON somato-dendritic oxytocin secretion enhances social recognition via actions in the MeA. 
609 The CeA contains oxytocin MNC axons collaterals but there are no oxytocin (MNC or parvocellular) 
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610 neurone axons in the MeA (17). OTRs are highly expressed in the MeA (222) and OTR antagonist 
611 injection into the MeA reduces social recognition induced by SON activation (225). However, MeA 
612 OTRs are not directly activated by oxytocin secreted into the CeA from MNC axon collaterals (17). 
613 The MeA lies immediately lateral to the SON and, even if somato-dendritic oxytocin secreted within 
614 the SON does not reach the MeA, some oxytocin MNC dendrites project to the MeA (225), which 
615 might deliver sufficient oxytocin to the MeA to promote social recognition. Alternatively, OTRs 
616 might be activated by vasopressin MNC axon collaterals in the MeA (19) because vasopressin has 
617 appreciable activity at OTRs (223).
618 Hormone-like modulation of neuronal activity in distant brain areas by somato-dendritic 
619 secretion from magnocellular neurosecretory cells
620 It has been hypothesised that somato-dendritic vasopressin and oxytocin from MNCs are a hormone-
621 like signal in the brain with widespread effects on distant populations of neurones (226). However, 
622 accumulating evidence of the functional impact of MNC axon collaterals on behaviour via direct 
623 projections to distant brain areas (17-21) have led to this hypothesis being challenged (227).
624 The half-lives of vasopressin and oxytocin are ~20 min in the cerebrospinal fluid (CSF) (228), giving 
625 time for diffusion through the ventricular system, particularly downstream. However, vasopressin (at 
626 least) has a half-life of less than 1 min in the parenchyma (229). Given that the paracrine effects of 
627 somato-dendritic vasopressin on preautonomic neurones that are only ~100 µm away is delayed by ~2 
628 – 5 s (193), it appears unlikely that the neuropeptides could diffuse long distances through the brain to 
629 act as a hormone-like signal. However, dense core vesicle exocytosis is a slow process compared to 
630 microvesicle fusion at the synapse, with latencies of several seconds in hippocampal neurones (230), 
631 which could account for much of the latency of the preautonomic neurone response to somato-
632 dendritic vasopressin secreted by MNCs in the PVN. Furthermore, vasopressin and oxytocin are 
633 secreted in sufficient quantities to be measured in dialysates collected from the SON and PVN (231), 
634 as well as in other brain areas (232-234) and in the cerebrospinal fluid (CSF) (235), suggesting that 
635 they diffuse through the parenchyma sufficiently to reach the CSF. Indeed, the microdialysis probes 
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636 used to measure vasopressin and oxytocin in many experiments have a recovery rate of <10% for 
637 vasopressin in the SON and PVN (236). Hence, it is likely that the actual concentrations of 
638 vasopressin and oxytocin present in the parenchyma and CSF are appreciably higher than those 
639 measured in dialysates. A further factor to be considered is retraction of astrocytic processes from 
640 around MNCs in dehydration and pregnancy (167, 168, 195, 196), which decreases tortuosity in the 
641 extracellular space, presumably allowing more ready escape of somato-dendritic vasopressin and 
642 oxytocin from the SON and PVN. It is difficult to imagine that the relatively sparse terminal fields of 
643 MNC axon collaterals and parvocellular vasopressin and oxytocin MNCs could release sufficient 
644 vasopressin and oxytocin to maintain the ambient levels of the neuropeptides found in the brain and 
645 CSF.
646 While there are clear examples of axon collaterals from sub-populations of MNCs affecting neuronal 
647 activity beyond the SON and PVN (237), this does not preclude the possibility that there is also long-
648 distance inter-population signalling mediated by somato-dendritic volume transmission of vasopressin 
649 and oxytocin over a longer timescale, particularly in brain regions in which there are neuropeptide 
650 receptors but no neuropeptide axons, such as in the olfactory bulb. Nevertheless, there is still no 
651 compelling evidence for, or against, distal hormone-like signalling by somato-dendritic vasopressin 
652 and oxytocin transmission, although the levels of oxytocin and vasopressin present in the 
653 cerebrospinal fluid and in brain areas devoid of oxytocin and vasopressin axon terminals appear to be 
654 much higher than could be achieved from axon terminal release from MNC and parvocellular axon 
655 collaterals. The resolution of this debate remains an ongoing challenge for the field.
656 Concluding remarks
657 Autocrine/paracrine modulation of MNC activity by somato-dendritic vasopressin and oxytocin 
658 release has been extensively studied and is broadly accepted as a major function of somato-dendritic 
659 secretion from MNCs (238). While it is clear that co-secreted transmitters also modulate MNC 
660 activity, there is no evidence of paracrine actions on other neurones, even other MNCs. Indeed, 
661 somato-dendritic dynorphin terminates bursts in the MNC from which it is secreted (70), but there is 
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662 no correlation between burst termination in phasic MNCs in paired recordings using a single electrode 
663 in which the recorded MNCs would be at most tens of micrometres apart (71), which is well within 
664 the range of somato-dendritic vasopressin but evidently beyond the range of somato-dendritic 
665 dynorphin. Hence, it is possible that co-secreted transmitters act as autocrine/paracrine modulators of 
666 the individual MNC from which they are secreted, whereas the much higher levels of vasopressin or 
667 oxytocin secreted modulate the activity of the population as a whole to regulate peripheral physiology.
668 Recently, compelling evidence has emerged that somato-dendritic secretion from MNCs modulates 
669 arteriole diameter in the SON (218) as well as the activity of neurones, particularly RVLM-projecting 
670 preautonomic neurones in the parvocellular PVN (193) (and perhaps also CRH neurones (216)). This 
671 inter-population cross-talk between MNCs and preautonomic neurones likely coordinates the 
672 hormonal (vasopressin secretion into the circulation) and neural (sympathetic nerve activation) 
673 response to perturbations of body fluid balance and blood pressure/volume (239). 
674 To date, there is no definitive evidence that somato-dendritic vasopressin and oxytocin have actions 
675 beyond the SON and PVN and it remains to be determined whether these neuropeptides act as 
676 hormone-like signals after secretion from MNC somata and dendrites. Nevertheless, while much of 
677 the data are circumstantial, it appears likely that somato-dendritic oxytocin release modulates the 
678 activity of neurones in some nearby brain areas that express OTRs but do not contain oxytocin (MNC 
679 or parvocellular) neurone projections, specifically the VMH (219, 222) and MeA (222, 225). The 
680 confirmation (or refutation) of the effects of somato-dendritic oxytocin on the VMH and/or MeA is 
681 required to resolve this ongoing debate within the field.
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1307 Figure legends
1308 Figure 1. Magnocellular neurosecretory cells. Magnocellular neurosecretory cells (MNCs) of the 
1309 hypothalamic supraoptic nucleus and paraventricular nucleus each possess 1 – 3 dendrites and project 
1310 a single axon to the posterior pituitary gland where they secrete either oxytocin or vasopressin into the 
1311 circulation. Some MNC axons project axon collaterals to other brains areas. 
1312 Figure 2. Mechanisms of somato-dendritic release of oxytocin from magnocellular 
1313 neurosecretory cells.  Neuropeptides are synthesized and packaged in the soma and stored in 
1314 dendrites in a reserve pool containing large numbers of large dense core vesicles (LDCVs). 
1315 Depolarization-induced calcium entry through voltage-gated calcium channels (VGCCs) stimulates 
1316 peptide release by exocytosis of LDCVs. This requires the depolymerization of F-actin to G-actin. 
1317 Furthermore, the stimulation of G-protein coupled receptors (GPR), such as the oxytocin receptor, 
1318 stimulates the mobilization of Ca2+ from IP3-dependent intracellular stores of the rough endoplasmic 
1319 reticulum (ER) and an increase in the number of LDCVs at the plasma membrane, thus priming the 
1320 exocytosis machinery for subsequent activity-dependent release. Although some members of the 
1321 SNARE family are detectable by immunocytochemistry, there appears to be a lack of VAMP, SNAP-
1322 25 and synaptotagmin-1 in the somata and dendrites, with their function presumably being replaced 
1323 by other SNARE proteins. 
1324 Figure 3. Autocrine modulation of burst firing in oxytocin magnocellular neurosecretory cells. 
1325 Cervical stretch during birth activates stretch receptors to activate A2 noradrenergic neurones in the 
1326 nucleus tractus solitarius (NTS) that, in turn, activates somato-dendritic oxytocin secretion from 
1327 oxytocin magnocellular neurosecretory cells (MNCs). Oxytocin feeds back on oxytocin MNCs to 
1328 increase excitability. Oxytocin also increases noradrenaline secretion within the SON to establishes a 
1329 local positive feedback loop that reinforces oxytocin MNC excitation and promotes oxytocin secretion 
1330 into the circulation to trigger uterine contractions during birth.
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1331 Figure 4. Ghrelin stimulation of somato-dendritic vasopressin secretion. Ghrelin activation of 
1332 growth hormone secretagogue receptors (GHSR) on vasopressin magnocellular neurosecretory cells 
1333 (MNCs) induces somato-dendritic vasopressin secretion, which activates V1a receptors (V1aRs) on 
1334 neighbouring astrocytes to increase intracellular calcium. Increased astrocytic calcium triggers release 
1335 of the gliotransmitter, ATP, which activates ionotropic P2X receptors on GABA interneurones that 
1336 project back to vasopressin MNCs. 
1337 Figure 5. Autocrine modulation of vasopressin magnocellular neurosecretory cell activity. 
1338 Vasopressin magnocellular neurosecretory cells (MNCs) secrete vasopressin, ATP and dynorphin 
1339 (and other transmitters) from their somata and dendrites. Endogenous AVP (2) inhibits spike 
1340 discharge throughout bursts via inhibition of EPSC amplitude. Endogenous ATP is rapidly converted 
1341 to adenosine (3), which enhances the medium afterhyperpolarisation (mAHP) amplitude over the first 
1342 few seconds of bursts to contribute to spike frequency adaptation. Endogenous dynorphin (4) 
1343 inhibition of the afterdepolarisation (ADP) increases progressively over the course of bursts, 
1344 eventually resulting in burst termination. Combined, these autocrine feedback effects of somato-
1345 dendritic vasopressin and co-secreted transmitters shape phasic activity for efficient secretion 
1346 vasopressin into the circulation from the posterior pituitary gland.
1347 Figure 6. Endocannabinoid modulation of excitatory and inhibitory synapses on MNCs. 
1348 Oxytocin activation of autocrine oxytocin receptors (OTR) on oxytocin neurons leads to a 
1349 tonic basal release of the endocannabinoid anandamide (AEA) at GABA synapses, which 
1350 tonically suppresses synaptic inhibitory input to oxytocin neurons by activating presynaptic 
1351 CB1 receptors. Depolarization (e.g., via action potential generation) or corticosteroid (Cort) 
1352 exposure (e.g., during stress) leads to a calcium-dependent release of the other main 
1353 endocannabinoid, 2-arachidonoylglycerol (2-AG), at glutamate synapses, which suppresses 
1354 synaptic excitation of both oxytocin and vasopressin MNCs by activating presynaptic CB1 
1355 receptors. Glial retraction induced by salt loading allows the 2-AG released at glutamate 
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1356 synapses to spill over onto GABA synapses and suppress synaptic inhibition via CB1 
1357 receptor activation. Tonic AEA occupation of CB1 receptors at GABA synapses is non-
1358 saturating, allowing additional suppression of GABA release following phasic 2-AG release 
1359 and synaptic spillover. 
1360 Figure 7. Paracrine actions of somato-dendritic vasopressin secretion. Activation of 
1361 neurosecretory vasopressin magnocellular neurosecretory cells (MNCs) (1) triggers action potential 
1362 firing (2) to release vasopressin into the circulation from the posterior pituitary gland (3). In parallel, 
1363 action potentials back-propagate into the dendrites (4) to trigger somato-dendritic vasopressin 
1364 secretion (5). In addition to autocrine feedback inhibition of vasopressin MNC activity via V1a 
1365 receptors (V1aRs) (6), somato-dendritic vasopressin diffuses through the extracellular space to bind to 
1366 V1aRs on presympathetic paraventricular nucleus neurones (7) to increase action potential firing (8) 
1367 and therefore increase sympathetic outflow to peripheral organs. Somato-dendritic vasopressin also 
1368 activates V1aRs on local blood vessels (9) to cause vasoconstriction, which is predicted to inhibit 
1369 vasopressin MNCs at a population level (10) by restricting the availability of oxygen and nutrients. 
1370 Hence, somato-dendritic vasopressin secretion coordinates neurohumoral responses to 
1371 (patho)physiological activation (11).
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Figure 1. Magnocellular neurosecretory cells. Magnocellular neurosecretory cells (MNCs) of the hypothalamic 
supraoptic nucleus and paraventricular nucleus each possess 1 – 3 dendrites and project a single axon to 
the posterior pituitary gland where they secrete either oxytocin or vasopressin into the circulation. Some 
MNC axons project axon collaterals to other brains areas. 
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Figure 2. Mechanisms of somato-dendritic release of oxytocin from magnocellular neurosecretory cells. 
 Neuropeptides are synthesized and packaged in the soma and stored in dendrites in a reserve pool 
containing large numbers of large dense core vesicles (LDCVs). Depolarization-induced calcium entry 
through voltage-gated calcium channels (VGCCs) stimulates peptide release by exocytosis of LDCVs. This 
requires the depolymerization of F-actin to G-actin. Furthermore, the stimulation of G-protein coupled 
receptors (GPR), such as the oxytocin receptor, stimulates the mobilization of Ca2+ from IP3-dependent 
intracellular stores of the rough endoplasmic reticulum (ER) and an increase in the number of LDCVs at the 
plasma membrane, thus priming the exocytosis machinery for subsequent activity-dependent release. 
Although some members of the SNARE family are detectable by immunocytochemistry, there appears to be 
a lack of VAMP, SNAP-25 and synaptotagmin-1 in the somata and dendrites, with their function presumably 
being replaced by other SNARE proteins. 
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Figure 3. Autocrine modulation of burst firing in oxytocin magnocellular neurosecretory cells. Cervical stretch 
during birth activates stretch receptors to activate A2 noradrenergic neurones in the nucleus tractus 
solitarius (NTS) that, in turn, activates somato-dendritic oxytocin secretion from oxytocin magnocellular 
neurosecretory cells (MNCs). Oxytocin feeds back on oxytocin MNCs to increase excitability. Oxytocin also 
increases noradrenaline secretion within the SON to establishes a local positive feedback loop that reinforces 
oxytocin MNC excitation and promotes oxytocin secretion into the circulation to trigger uterine contractions 
during birth. 
179x181mm (300 x 300 DPI) 





























































For Peer Review Only
 
Figure 4. Ghrelin stimulation of somato-dendritic vasopressin secretion. Ghrelin activation of growth 
hormone secretagogue receptors (GHSR) on vasopressin magnocellular neurosecretory cells (MNCs) induces 
somato-dendritic vasopressin secretion, which activates V1a receptors (V1aRs) on neighbouring astrocytes 
to increase intracellular calcium. Increased astrocytic calcium triggers release of the gliotransmitter, ATP, 
which activates ionotropic P2X receptors on GABA interneurones that project back to vasopressin MNCs. 
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Figure 5. Autocrine modulation of vasopressin magnocellular neurosecretory cell activity. Vasopressin 
magnocellular neurosecretory cells (MNCs) secrete vasopressin, ATP and dynorphin (and other transmitters) 
from their somata and dendrites. Endogenous AVP (2) inhibits spike discharge throughout bursts via 
inhibition of EPSC amplitude. Endogenous ATP is rapidly converted to adenosine (3), which enhances the 
medium afterhyperpolarisation (mAHP) amplitude over the first few seconds of bursts to contribute to spike 
frequency adaptation. Endogenous dynorphin (4) inhibition of the afterdepolarisation (ADP) increases 
progressively over the course of bursts, eventually resulting in burst termination. Combined, these autocrine 
feedback effects of somato-dendritic vasopressin and co-secreted transmitters shape phasic activity for 
efficient secretion vasopressin into the circulation from the posterior pituitary gland. 
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Figure 6. Endocannabinoid modulation of excitatory and inhibitory synapses on MNCs. Oxytocin activation of 
autocrine oxytocin receptors (OTR) on oxytocin neurons leads to a tonic basal release of the 
endocannabinoid anandamide (AEA) at GABA synapses, which tonically suppresses synaptic inhibitory input 
to oxytocin neurons by activating presynaptic CB1 receptors. Depolarization (e.g., via action potential 
generation) or corticosteroid (Cort) exposure (e.g., during stress) leads to a calcium-dependent release of 
the other main endocannabinoid, 2-arachidonoylglycerol (2-AG), at glutamate synapses, which suppresses 
synaptic excitation of both oxytocin and vasopressin MNCs by activating presynaptic CB1 receptors. Glial 
retraction induced by salt loading allows the 2-AG released at glutamate synapses to spill over onto GABA 
synapses and suppress synaptic inhibition via CB1 receptor activation. Tonic AEA occupation of CB1 
receptors at GABA synapses is non-saturating, allowing additional suppression of GABA release following 
phasic 2-AG release and synaptic spillover. 
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Figure 7. Paracrine actions of somato-dendritic vasopressin secretion. Activation of neurosecretory 
vasopressin magnocellular neurosecretory cells (MNCs) (1) triggers action potential firing (2) to release 
vasopressin into the circulation from the posterior pituitary gland (3). In parallel, action potentials back-
propagate into the dendrites (4) to trigger somato-dendritic vasopressin secretion (5). In addition to 
autocrine feedback inhibition of vasopressin MNC activity via V1a receptors (V1aRs) (6), somato-dendritic 
vasopressin diffuses through the extracellular space to bind to V1aRs on presympathetic paraventricular 
nucleus neurones (7) to increase action potential firing (8) and therefore increase sympathetic outflow to 
peripheral organs. Somato-dendritic vasopressin also activates V1aRs on local blood vessels (9) to cause 
vasoconstriction, which is predicted to inhibit vasopressin MNCs at a population level (10) by restricting the 
availability of oxygen and nutrients. Hence, somato-dendritic vasopressin secretion coordinates 
neurohumoral responses to (patho)physiological activation (11). 
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